Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Medicinal marijuana: Patients battle stigma and misunderstanding

  • CPR: It's not always a lifesaver, but it plays one on TV

  • Goth teens could be more vulnerable to depression and self-harm

  • Brain scans predict response to antipsychotic medications

  • Older adults possess important forms of expertise

  • Covert and overt forms of sexism are equally damaging to working women

  • Retinoids may increase effectiveness of targeted therapies against high-risk leukemia

  • Air pollution linked to children's low academic achievement

  • Turning breath into words: New device unveiled to give paralysis victims a voice

  • Neurobiology: Light-activated learning

  •